2024-02-15 13:39:09 ET
Royalty Pharma PLC (RPRX)
Q4 2023 Earnings Conference Call
February 15, 2024, 8:00 a.m. ET
Company Participants
Pablo Legorreta - Founder, Chairman & CEO
Chris Hite - Vice Chairman & EVP
Terrance Coyne - EVP & CFO
Marshall Urist - EVP & Head, Research & Investments
George Grofik - SVP & Head of IR & Communications
Conference Call Participants
Geoff Meacham - Bank of America
Chris Schott - J.P. Morgan
Terence Flynn - Morgan Stanley
Chris Shibutani - Goldman Sachs
Steve Scala - TD Cowen
Presentation
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Q4 2023 Earnings Conference Call. I would like now to turn the conference over to George Grofik, Senior Vice President, Head of Investor Relations, and Communications. Please go ahead.
George Grofik
Thank you. Good morning, and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's Fourth Quarter and Full-Year 2023 results. You can find the press release with our earnings results and slides of the call on the Investors page of our website at Royaltypharma.com.
Moving to Slide 3, I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from these statements. I refer you to our 10-K on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma, and we assume no obligation to update any such forward-looking statements. Non-GAAP liquidity measures will be used to help you understand our financial performance. The reconciliation of these measures to our GAP financials are provided in the earnings press release available on our website. ...
Read the full article on Seeking Alpha
For further details see:
Royalty Pharma PLC (RPRX) Q4 2023 Earnings Call Transcript